# The Norwegian Tenecteplase Stroke Trial 2

Study · id `cardio:ct-nct03854500` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03854500](<https://clinicaltrials.gov/study/NCT03854500>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03854500

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 201 participants.

## Technical summary

Registry record NCT03854500. Randomized; double masking; primary purpose treatment. Start 2019-10-28 (actual); primary completion 2021-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 201 participants (enrolled count; ClinicalTrials.gov record NCT03854500, source copy `cardio:ctgov-nct03854500-2025-03-03`, retrieved 2026-10-26)
- Started: 2019-10-28 (actual) (ClinicalTrials.gov record NCT03854500, source copy `cardio:ctgov-nct03854500-2025-03-03`, retrieved 2026-10-26)
- Primary completion: 2021-09-30 (actual) (ClinicalTrials.gov record NCT03854500, source copy `cardio:ctgov-nct03854500-2025-03-03`, retrieved 2026-10-26)
- Completion: 2021-12-31 (actual) (ClinicalTrials.gov record NCT03854500, source copy `cardio:ctgov-nct03854500-2025-03-03`, retrieved 2026-10-26)
- Countries: Norway (ClinicalTrials.gov record NCT03854500, source copy `cardio:ctgov-nct03854500-2025-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03854500-2025-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Norwegian Tenecteplase Stroke Trial 2
- Acronym: NOR-TEST 2
- Condition: Stroke, Acute
- Condition: Cerebrovascular Disorders
- Condition: Ischemic Stroke
- Intervention (Drug): Tenecteplase
- Intervention (Drug): Alteplase
- Lead sponsor: Haukeland University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Tenecteplase (`cardio:tenecteplase`)
- Registry lists this organization as the lead sponsor: Haukeland University Hospital (`cardio:org-haukeland-university-hospital`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial (`cardio:pubmed-35525250`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6d40df9bb6592a57277eaff80aee0690ebe2edfe437fd9a4d43de37df8d75d4b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
